Page last updated: 2024-10-25

ciglitazone and Neoplasms

ciglitazone has been researched along with Neoplasms in 2 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Papi, A1
Rocchi, P1
Ferreri, AM1
Guerra, F1
Orlandi, M1
Marra, F1
Pastacaldi, S1

Reviews

1 review available for ciglitazone and Neoplasms

ArticleYear
[Thiazolidinediones and PPARgamma system in repair of liver damage].
    Recenti progressi in medicina, 2002, Volume: 93, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chro

2002

Other Studies

1 other study available for ciglitazone and Neoplasms

ArticleYear
Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells.
    Oncology reports, 2009, Volume: 21, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Synergism; Humans; Matrix Metalloprotei

2009